Experimental validation of data mined single nucleotide polymorphisms from several databases and consecutive dbSNP builds.

Abstract:

:Rapid development in the annotation of human genetic variation has increased the numbers of single nucleotide polymorphisms (SNPs) in candidate genes by several orders of magnitude. The selection of both useful target SNPs for disease-gene association studies and SNPs associated with the treatment response is therefore an increasingly challenging task. We describe a workflow for selecting SNPs based on their putative function and frequency in candidate genes extracted from PubMed resources. The annotation of each SNP and its frequency in a Caucasian population was assessed in several databases. Approximately 4000 SNPs were identified from an initial 233 candidate genes. In a case study, we performed actual genotyping of 1030 of these SNPs in 213 genes and obtained 710 successfully genotyped SNPs. Using the flow-chart outlined here, only 87 SNPs were monomorphic (approximately 12%). This study reports the frequency of SNPs in a Caucasian population, selected in silico, using a candidate gene approach and validated by actually genotyping 193 individuals. The selected genotypes represent a valuable set of verified candidate SNPs for pharmacogenetic studies in Caucasian populations.

journal_name

Pharmacogenet Genomics

authors

Edvardsen H,Irene Grenaker Alnaes G,Tsalenko A,Mulcahy T,Yuryev A,Lindersson M,Lien S,Omholt S,Syvänen AC,Børresen-Dale AL,Kristensen VN

doi

10.1097/01.fpc.0000194422.12770.fb

keywords:

subject

Has Abstract

pub_date

2006-03-01 00:00:00

pages

207-17

issue

3

eissn

1744-6872

issn

1744-6880

pii

01213011-200603000-00007

journal_volume

16

pub_type

杂志文章
  • Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers.

    abstract:BACKGROUND AND OBJECTIVES:Quetiapine is an atypical antipsychotic drug used to treat schizophrenia and acute episodes of mania. Quetiapine is metabolized by CYP3A enzymes including CYP3A5 and is a substrate of P-glycoprotein, an efflux drug transporter encoded by the ABCB1 gene. We assessed the effects of ABCB1 [c.1236...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000020

    authors: Kim KA,Joo HJ,Lee HM,Park JY

    更新日期:2014-01-01 00:00:00

  • Functional assessment of genetic variants located in the promoter of SHP1 (NR0B2).

    abstract::Small heterodimer partner 1 (SHP1, NR0B2) is a member of the superfamily of nuclear receptors (NRs). Even if this orphan receptor, unlike other NRs, lacks the DNA-binding domain, it is capable of regulating transcription by repressing the activity of other NRs by direct protein-protein interaction. Accordingly, SHP1 i...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000310

    authors: Prestin K,Olbert M,Hussner J,Völzke H,Meyer Zu Schwabedissen HE

    更新日期:2017-11-01 00:00:00

  • Association between two key SNPs on chromosome 12p13 and ischemic stroke in Chinese Han population.

    abstract:OBJECTIVE:Genome-wide single nucleotide polymorphism (SNP) association studies recently identified two SNPs (rs11833579 and rs12425791) on chromosome 12p13 that are associated with ischemic stroke (IS) in Caucasian or Black persons from America and the Netherlands. Our aim was to determine whether these SNPs were assoc...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e32834911d0

    authors: Tong Y,Zhang Y,Zhang R,Geng Y,Lin L,Wang Z,Liu J,Li X,Cao Z,Xu J,Chai Y,Fan H,Hu FB,Lu Z,Cheng J

    更新日期:2011-09-01 00:00:00

  • Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.

    abstract:OBJECTIVE:The effects of various polymorphisms in cytochrome P450 (CYP) enzyme and transporter genes on the pharmacokinetics (PK) of simvastatin were evaluated in healthy Korean men. METHODS:Plasma concentration data for simvastatin and simvastatin acid were pooled from four phase I studies comprising 133 participants...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/FPC.0000000000000176

    authors: Choi HY,Bae KS,Cho SH,Ghim JL,Choe S,Jung JA,Jin SJ,Kim HS,Lim HS

    更新日期:2015-12-01 00:00:00

  • Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers.

    abstract:INTRODUCTION:Cytochrome P450 1A2 (CYP 1A2) is responsible for more than 90% of caffeine clearance. A polymorphic variant of CYP1A2 (-163C>A) (rs762551) is associated with high CYP1A2 inducibility. Both caffeine and its main metabolite, paraxanthine, may be neuroprotective. The association between caffeine intake and ri...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3282f09265

    authors: Tan EK,Chua E,Fook-Chong SM,Teo YY,Yuen Y,Tan L,Zhao Y

    更新日期:2007-11-01 00:00:00

  • Common ABCB1 polymorphisms are not associated with multidrug resistance in epilepsy using a gene-wide tagging approach.

    abstract::P-glycoprotein, the product of the ABCB1 gene, is a proposed mechanism of pharmacoresistance in epilepsy. Previous attempts to correlate the ABCB1 C3435T SNP, or a three-SNP haplotype containing C3435T with epilepsy pharmacoresistance have produced discordant findings. We analysed these single nucleotide polymorphisms...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章,meta分析

    doi:10.1097/01.fpc.0000230408.23146.b1

    authors: Leschziner GD,Andrew T,Leach JP,Chadwick D,Coffey AJ,Balding DJ,Bentley DR,Pirmohamed M,Johnson MR

    更新日期:2007-03-01 00:00:00

  • The rs13064411 polymorphism in the WDR52 gene, associated with PCSK9 levels, modifies statin-induced changes in serum total and LDL cholesterol levels.

    abstract:OBJECTIVE:Recently, the minor allele of the rs13064411A>G polymorphism in the WD repeat domain 52 (WDR52) gene was associated with increased statin-induced proprotein convertase subtilisin/kexin type 9 (PCSK9) levels and with LDL cholesterol response to statins. PCSK9 promotes LDL receptor degradation, leading to incre...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000120

    authors: de Keyser CE,Becker ML,Hofman A,Lous JJ,Uitterlinden AG,Visser LE,Stricker BH

    更新日期:2015-03-01 00:00:00

  • Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes.

    abstract:OBJECTIVES:Nine different functional UGT1A enzymes are generated from a single UGT1A gene by alternative splicing, with each enzyme having a unique exon 1. SN-38, the active metabolite of the anticancer agent irinotecan, is metabolized by both UGT1A1 and UGT1A9. We aim to characterize the UGT1A9-UGT1A1 haplotypes in As...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/01213011-200505000-00004

    authors: Innocenti F,Liu W,Chen P,Desai AA,Das S,Ratain MJ

    更新日期:2005-05-01 00:00:00

  • Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity.

    abstract:OBJECTIVE:To determine whether polymorphisms in the sulfonamide detoxification genes, CYB5A (encoding cytochrome b(5)), CYB5R3 (encoding cytochrome b(5) reductase), or NAT2 (encoding N-acetyltransferase 2) were over-represented in patients with delayed sulfonamide drug hypersensitivity, compared with control patients w...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e328357a735

    authors: Sacco JC,Abouraya M,Motsinger-Reif A,Yale SH,McCarty CA,Trepanier LA

    更新日期:2012-10-01 00:00:00

  • Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips.

    abstract:OBJECTIVES:Numerous functional polymorphisms in the CYP2C19 gene have been identified; some alleles (e.g. CYP2C19*2 and CYP2C19*3) are associated with poor metabolism of CYP2C19 substrate drugs. Studies have found that the proportion of poor metabolizers, explained by CYP2C19*2 and CYP2C19*3, varies from less than 50% ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e32801152c2

    authors: Nakamoto K,Kidd JR,Jenison RD,Klaassen CD,Wan YJ,Kidd KK,Zhong XB

    更新日期:2007-02-01 00:00:00

  • Angiotensin-converting enzyme insertion/deletion gene polymorphism and interferon-β treatment response in multiple sclerosis patients: a preliminary report.

    abstract::We investigated the effect of the functional insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme (ACE) gene on the response to interferon-β (IFN-β) therapy in Croatian and Slovenian patients with multiple sclerosis (MS). A total of 275 IFN-β treated MS patients [162 responders (Rs) and 113 nonre...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000283

    authors: Ristić S,Starčević Čizmarević N,Lavtar P,Lovrečić L,Perković O,Sepčić J,Šega Jazbec S,Kapović M,Peterlin B

    更新日期:2017-06-01 00:00:00

  • Hepatocyte nuclear factor1 transcription factors are essential for the UDP-glucuronosyltransferase 1A9 promoter response to hepatocyte nuclear factor 4alpha.

    abstract::In humans, UDP-glucuronosyltransferase 1A9 is known to glucuronidate numerous lipophilic substances of pharmacological and toxicological importance. Although it has been established that individuals vary in their capacity to express this detoxification enzyme, little is known about the mechanisms that dictate the regu...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e32801112b5

    authors: Gardner-Stephen DA,Mackenzie PI

    更新日期:2007-01-01 00:00:00

  • Functional consequences of nonsynonymous single nucleotide polymorphisms in the CB2 cannabinoid receptor.

    abstract:OBJECTIVE:To test the hypothesis that the two nonsynonymous single nucleotide polymorphisms at the CB2 cannabinoid receptor gene may have functional consequences on human CB2. METHODS:Q63R, H316Y, and Q63R/H316 mutations were made in recombinant human CB2 by the method of site-directed mutagenesis. After these mutant ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3283367c6b

    authors: Carrasquer A,Nebane NM,Williams WM,Song ZH

    更新日期:2010-03-01 00:00:00

  • Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.

    abstract:OBJECTIVE:The immunosuppressive drug tacrolimus requires strict therapeutic monitoring due to its narrow therapeutic index and great inter-individual variability. Cytochrome P450 3A4 (Cyp3A4) and Cyp3A5 are the most important contributors to tacrolimus metabolism while the P-glycoprotein pump (MDR-1) modulates its bioa...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/01.fpc.0000220571.20961.dd

    authors: Roy JN,Barama A,Poirier C,Vinet B,Roger M

    更新日期:2006-09-01 00:00:00

  • Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.

    abstract:INTRODUCTION:Elevated plasma homocysteine (Hcy) concentration is an independent risk factor for cardiovascular disease, and its involvement in endothelial cell dysfunction is well established. However, the role of Hcy and folate in the pathogenesis of Parkinson's disease (PD) remains controversial. OBJECTIVES:The stud...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e32835693f7

    authors: Białecka M,Kurzawski M,Roszmann A,Robowski P,Sitek EJ,Honczarenko K,Gorzkowska A,Budrewicz S,Mak M,Jarosz M,Gołąb-Janowska M,Koziorowska-Gawron E,Droździk M,Sławek J

    更新日期:2012-10-01 00:00:00

  • Deciphering ADME genetic data using an automated haplotype approach.

    abstract:OBJECTIVE:To investigate the utility of statistical tools in translating Affymetrix Drug Metabolizing Enzyme and Transporter (DMET) Assay single-nucleotide polymorphisms (SNPs) into common consensus star alleles. METHODS:DMET SNP data from clinical trials in different ethnicities were pooled for analyses. Three differ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000047

    authors: Guo Y,Farmen MW,Jin Y,Lee HY,Penny MA,Hillgren KM,Fossceco SL

    更新日期:2014-06-01 00:00:00

  • A novel ABCC6 haplotype is associated with azathioprine drug response in myasthenia gravis.

    abstract:OBJECTIVE:We investigated the association of single nucleotide polymorphisms (SNPs) in drug-metabolizing enzymes and transporters (DMETs) with the response to azathioprine (AZA) in patients affected by myasthenia gravis (MG) to determine possible genotype-phenotype correlations. PATIENTS AND METHODS:Genomic DNA from 1...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000257

    authors: Colleoni L,Galbardi B,Barzago C,Bonanno S,Franzi S,Frangiamore R,Camera G,Foti M,Biancolini D,Canioni E,Maggi L,Antozzi C,Mantegazza R,Bernasconi P,Kapetis D

    更新日期:2017-02-01 00:00:00

  • Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression.

    abstract:OBJECTIVES:Epidemiological studies documented associations between single nucleotide polymorphisms (SNPs) in the nucleotide excision repair gene XPD/ERCC2 and cancer risk. Little is known, however, about the underlying mechanisms for these associations. We explored a novel mechanism that could further explain the repor...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3280115e63

    authors: Wolfe KJ,Wickliffe JK,Hill CE,Paolini M,Ammenheuser MM,Abdel-Rahman SZ

    更新日期:2007-11-01 00:00:00

  • MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.

    abstract:BACKGROUND:Despite the enormous success of imatinib in chronic myeloid leukemia (CML), therapy resistance has emerged in a significant proportion of patients, partly because of the overexpression of ABC efflux transporters. METHODS:Using an array comprising 667 miRNAs, we investigated whether the expression of microRN...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e328350012b

    authors: Turrini E,Haenisch S,Laechelt S,Diewock T,Bruhn O,Cascorbi I

    更新日期:2012-03-01 00:00:00

  • Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab.

    abstract::The study aimed to investigate whether polymorphisms in genes of the EGFR signaling pathway are associated with clinical outcome in advanced colorectal cancer (CRC) patients treated with single-agent Cetuximab. Polymorphisms of interest in the EGFR pathway include: cyclin D1 (CCND1) A870G, cyclooxygenase 2 (Cox-2) G-7...

    journal_title:Pharmacogenetics and genomics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/01.fpc.0000220562.67595.a5

    authors: Zhang W,Gordon M,Press OA,Rhodes K,Vallböhmer D,Yang DY,Park D,Fazzone W,Schultheis A,Sherrod AE,Iqbal S,Groshen S,Lenz HJ

    更新日期:2006-07-01 00:00:00

  • A candidate-gene association study of topiramate-induced weight loss in obese patients with and without type 2 diabetes mellitus.

    abstract:OBJECTIVE:Clinical response to topiramate can vary greatly in obese patients. Identifying genetic variants associated with treatment response could help gain insight into the mechanism of action of topiramate. Little is known about the relationship between genetic variability and topiramate treatment response. We perfo...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000185

    authors: Li QS,Lenhard JM,Zhan Y,Konvicka K,Athanasiou MC,Strauss RS,Francke S

    更新日期:2016-02-01 00:00:00

  • Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions.

    abstract:BACKGROUND:Co-trimoxazole is a sulfonamide-containing antibiotic that is effective in the treatment of several infections and for prophylaxis of Pneumocystis jiroveci pneumonia. This drug has been reported as a common culprit drug for the Stevens-Johnson syndrome (SJS) and for toxic epidermal necrolysis (TEN). Human le...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000153

    authors: Kongpan T,Mahasirimongkol S,Konyoung P,Kanjanawart S,Chumworathayi P,Wichukchinda N,Kidkeukarun R,Preechakul S,Khunarkornsiri U,Bamrungram W,Supharatwattanakun B,Mootsikapun P,Kwangsukstid S,Denjanta S,Vannaprasaht S,Rungap

    更新日期:2015-08-01 00:00:00

  • Polymorphisms in mitochondrial genes encoding complex I subunits are maternal factors of voluntary alcohol consumption in the rat.

    abstract:OBJECTIVE:Alcohol is detoxified in the liver by oxidizing enzymes that require nicotinamide adenine dinucleotide (NAD+) such that, in the rat, the availability of NAD+ contributes to control voluntary ethanol intake. The UChA and UChB lines of Wistar rats drink low and high amounts of ethanol respectively and differ in...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e32832dc12a

    authors: Sapag A,González-Martínez G,Lobos-González L,Encina G,Tampier L,Israel Y,Quintanilla ME

    更新日期:2009-07-01 00:00:00

  • Multidrug resistance-related protein 2 genotype of the donor affects kidney graft function.

    abstract:OBJECTIVES:We tested the effect of kidney-specific multidrug resistance-related protein (MRP2, ABCC2) deficiency on renal organic solute disposition as well as on renal protein and gene expression. Furthermore, we investigated whether a particular kidney donor ABCC2 genotype is associated with delayed graft function in...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e328328d4e9

    authors: Grisk O,Steinbach AC,Ciecholewski S,Schlüter T,Klöting I,Schmidt H,Dazert E,Schaeffeler E,Steil L,Gauer S,Jedlitschky G,Schwab M,Geisslinger G,Hauser IA,Völker U,Kroemer HK,Rettig R

    更新日期:2009-04-01 00:00:00

  • Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapy.

    abstract:OBJECTIVE:Niacin has been used for seven decades to modulate plasma lipids, but its mechanism of action is still unclear. We sought to determine whether variants in the niacin receptor gene, hydroxyl-carboxylic receptor 2 (HCAR2), are associated with lipid response to treatment. PARTICIPANTS AND METHODS:Coding variant...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/FPC.0000000000000289

    authors: Tuteja S,Wang L,Dunbar RL,Chen J,DerOhannessian S,Marcovina SM,Elam M,Lader E,Rader DJ

    更新日期:2017-08-01 00:00:00

  • The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers.

    abstract:OBJECTIVE:We investigated whether the UGT1A3 polymorphisms play an important role in interindividual variations in atorvastatin lactonization and lipid-lowering effect. METHODS:Twenty-three healthy volunteers were administered atorvastatin 20 mg once daily for 14 days. Serum levels of lipids were measured before and 7...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3283544085

    authors: Cho SK,Oh ES,Park K,Park MS,Chung JY

    更新日期:2012-08-01 00:00:00

  • Effect of angiotensin-converting enzyme tag single nucleotide polymorphisms on the outcome of patients with traumatic brain injury.

    abstract:BACKGROUND:Genetic variants appear to influence, at least to some degree, the extent of brain injury and the clinical outcome of patients who have sustained a traumatic brain injury (TBI). Angiotensin-converting enzyme (ACE) is a zinc metallopeptidase that is implicated in the regulation of blood pressure and cerebral ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000161

    authors: Dardiotis E,Paterakis K,Siokas V,Tsivgoulis G,Dardioti M,Grigoriadis S,Simeonidou C,Komnos A,Kapsalaki E,Fountas K,Hadjigeorgiou GM

    更新日期:2015-10-01 00:00:00

  • Association of Cullin1 haplotype variants with rheumatoid arthritis and response to methotrexate.

    abstract::Aberrations in ubiquitin pathway have been implicated in many diseases and drug response. In a previous study on rheumatoid arthritis (RA) in Japanese population, significant association of Cullin1 gene (CUL1), an ubiquitin E3 ligase, was observed. CUL1 also mediates degradation of IκBα and p27, levels of which has be...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3283492af7

    authors: Negi S,Kumar A,Thelma BK,Juyal RC

    更新日期:2011-09-01 00:00:00

  • Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

    abstract:OBJECTIVES:The aim of this study was to evaluate the effect of polymorphisms affecting the clopidogrel metabolism (CYP3A4 IVS10+12G/A and CYP2C19*2) and the P2Y12 receptor (P2Y12 T744C) on modulating platelet function in acute coronary syndrome patients on dual antiplatelet treatment. BACKGROUND:Residual platelet reac...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3282f1b2be

    authors: Giusti B,Gori AM,Marcucci R,Saracini C,Sestini I,Paniccia R,Valente S,Antoniucci D,Abbate R,Gensini GF

    更新日期:2007-12-01 00:00:00

  • Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma.

    abstract:BACKGROUND:Although several studies have shown that drug metabolizing enzyme gene polymorphisms may influence the impact of therapy in childhood leukemia, no comprehensive investigations have been carried out in children with neuroblastoma. The aim of this study was to identify polymorphisms in the genes encoding phase...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3280e1cc92

    authors: Ashton LJ,Murray JE,Haber M,Marshall GM,Ashley DM,Norris MD

    更新日期:2007-09-01 00:00:00